Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylate cyclase-activating protein 1 (GCAP1) is a neuronal calcium sensor protein primarily expressed in rod and cone photoreceptors of the retina. It detects changes in intracellular Ca²⁺ concentration and acts as a molecular switch: at low Ca²⁺ (light-adapted state), GCAP1 binds Mg²⁺ and activates retinal guanylate cyclase (RetGC), promoting the synthesis of cyclic GMP necessary for photoresponse recovery; at high Ca²⁺ (dark state), GCAP1 inhibits RetGC to maintain cGMP homeostasis. This regulation is crucial for visual processing and photoreceptor viability. GCAP1 contains multiple EF-hand domains for Ca²⁺/Mg²⁺ binding and is myristoylated at its N-terminus. Pathogenic mutations in GUCA1A can disrupt the calcium-sensing or regulatory function, resulting in inherited forms of retinal degeneration, especially various cone and cone-rod dystrophies, due to altered cGMP and Ca²⁺ homeostasis in photoreceptors[1][2][3][4][5].
Allosteric modulation of retinal guanylate cyclase (RetGC) activity (activation at low Ca²⁺/Mg²⁺-bound, inhibition at high Ca²⁺) Mutant forms can constitutively activate RetGC leading to photoreceptor pathology
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylate cyclase-activating protein 1 (GCAP1).